A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
Clinical trial NCT03090100 · COMPLETED
Trial details
- NCT number
- NCT03090100
- Sponsor
- Janssen Research & Development, LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-04-27
- Primary completion
- 2018-08-02
- Enrollment
- 1048
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.